Dr. Philippe Nabbout, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 1,183
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
OK license 28055
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Via Christi Hospitals Wichita, Inc. Wichita, KS
- Wesley Medical Center Wichita, KS
- Nmc Health Newton, KS
- Kansas Medical Center LLC Andover, KS
- Kansas Surgery & Recovery Center Wichita, KS
Medical groups
- Wichita Urology Group PA (30 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,183
- Services billed
- 15,029
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,900 | 35 |
| Injection, denosumab, 1 mg | 2,100 | 12 |
| Bcg live intravesical instillation, 1 mg | 686 | 24 |
| Established patient office or other outpatient visit, 20-29 minutes | 391 | 335 |
| Ultrasound measurement of bladder capacity after voiding | 342 | 288 |
| Established patient office or other outpatient visit, 30-39 minutes | 337 | 266 |
| New patient office or other outpatient visit, 45-59 minutes | 280 | 280 |
| Insertion of needle into vein for collection of blood sample | 237 | 224 |
| Diagnostic exam of bladder and urethra using an endoscope | 215 | 192 |
| Psa (prostate specific antigen) measurement, total | 197 | 187 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Wichita, KS | 715 |
| Orgovyx (relugolix) | 285 |
| Gemtesa (vibegron) Other prescribers in Wichita, KS | 203 |
| Cephalexin Other prescribers in Wichita, KS | 185 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Wichita, KS | 115 |
| Myrbetriq (mirabegron) Other prescribers in Wichita, KS | 99 |
| Solifenacin Succinate Other prescribers in Wichita, KS | 90 |
| Xtandi (enzalutamide) | 76 |
| Oxybutynin Chloride Other prescribers in Wichita, KS | 74 |
| Erleada (apalutamide) | 64 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 23 payments worth $4,898 in total to this clinician.
| Ferring Pharmaceuticals Inc. | $2,555 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $1,481 |
| Boston Scientific Corporation | $266 |
| Immunitybio, Inc. | $119 |
| Novartis Pharmaceuticals Corporation | $96.55 |
| Janssen Biotech, Inc. | $84.99 |
| Medtronic, Inc. | $82.38 |
| Pfizer Inc. | $65.81 |
| Consulting Fee | $3,896 |
|---|---|
| Food and Beverage | $918 |
| Education | $84.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ferring Pharmaceuticals Inc. Oct 20, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,415 |
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Consulting Fee | $1,481 |
| Janssen Biotech, Inc. May 19, 2025 | Education ERLEADA · Oncology · in-kind | $84.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $87,295 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Ironwood Pharmaceuticals, Inc - A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06545955 - Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374 - A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible …
Janssen Research & Development, LLC - ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Ferring Pharmaceuticals As · Terminated · NCT06026332
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.